Indian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatment for advanced prostate cancer. This approval covers multiple strengths, including 40 mg, 80 mg, 120 mg, and 160 mg. The company's offering is bioequivalent to the reference drug, Xtandi, and aims to provide more flexible dosing options for patients and medical professionals.